This maneuver can result in efficient local priming of tumor‐specific CD8+ T cells that are to be de‐repressed by checkpoint inhibitors in triple regimens for cancer immunotherapy, in an attempt to attain synergistic effects in the clinic. This evidence concerns the gene CD8A and cancer.